Vigil Neuroscience, a biotechnology company specializing in neurodegenerative disease treatment, will have its President and CEO, Ivana Magovčević-Liebisch, and Chief Science Officer, David Gray, participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference.
Vigil Neuroscience to Present at Guggenheim Biotechnology Conference
( Credit to: Globenewswire )
Vigil Neuroscience, a biotechnology company specializing in the treatment of neurodegenerative diseases, is set to make an appearance at the Guggenheim 6th Annual Biotechnology Conference. The President and CEO, Ivana Magovčević-Liebisch, Ph.D., J.D., and Chief Science Officer, David Gray, Ph.D., will be participating in a fireside chat during the event.
With a focus on harnessing the power of microglia, the immune cells of the brain, Vigil Neuroscience aims to develop precision-based therapies for neurodegenerative diseases. By restoring the vigilance of microglia, the company strives to improve the lives of patients and their families.
Targeting Neurodegenerative Diseases with Microglia-Based Therapies
One of Vigil's lead clinical candidates is Iluzanebart, a fully human monoclonal antibody agonist that targets the human triggering receptor expressed on myeloid cells 2 (TREM2). This treatment is specifically developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
In addition to Iluzanebart, Vigil is also working on VG-3927, a novel small molecule TREM2 agonist. This therapy is being developed to address common neurodegenerative diseases associated with microglial dysfunction, with a primary focus on Alzheimer's disease (AD) in genetically defined subpopulations.
Join the Fireside Chat and Stay Informed
Investors and interested parties have the opportunity to register for the live fireside chat event by visiting Vigil Neuroscience's website. The webcast will also be available on the company's "Events & Presentations" page in the "Investors" section. For those unable to attend the live event, an archived webcast will be accessible for approximately 90 days following the presentation.
Vigil Neuroscience encourages individuals to regularly visit the "Investors" section of its website for updates and relevant information. For further inquiries, please contact Leah Gibson, Vice President of Investor Relations & Corporate Communications at Vigil Neuroscience. Media inquiries can be directed to Megan McGrath of MacDougall Advisors.